Subcutaneous Lecanemab Maintenance Dosing for Alzheimer’s Supported by New Data

(MedPage Today) — TORONTO — An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of lecanemab (Leqembi) for maintenance treatment in early Alzheimer’s disease, researchers said here.
Continued…